Weight Loss Injections News: What's Actually Changed and Why It Matters

The new Wegovy pen and what a higher dose means in practice

For a long time, 2.4 mg once weekly was the ceiling for injectable semaglutide. That changed on 14 April 2026, when the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, a pre-set weekly injection with a covered needle that locks after use. The approval announcement published on GOV.UK confirmed this is licensed for adults with a BMI of 30 or above. Crucially, you still start at 0.25 mg and step up through the existing schedule under a prescriber's guidance, 7.2 mg is the new maximum, not the starting point.

Trial data at the higher dose showed roughly 20.7% average weight reduction over 72 weeks, which narrows the gap considerably compared with the best tirzepatide results. That said, deciding which medicine is likely to suit you involves far more than headline percentages: your medical history, any other medicines you take, and how your body has responded before all feed into the conversation. If you're weighing up the two options, our overview of the three main licensed injections sets out the differences clearly. No single figure settles the question.

The 7.2 mg licence applies to weight management only, not the cardiovascular or liver-disease indications that semaglutide also holds. And it applies at a BMI of 30 or above, not the 27-plus threshold available when a weight-related condition is present. Worth checking against your own numbers before assuming you'd qualify for the top dose.

The NHS rollout of tirzepatide: where the eligibility lines sit now

The NHS expansion of tirzepatide (Mounjaro) is running in phases tied to NICE's appraisal TA1026, published in December 2024. A first cohort (adults with a BMI of 40 or above plus four or more of five qualifying conditions) became eligible from June 2025. A second cohort, covering adults with a BMI of 35 to 39.9 plus four or more of those conditions, opened in June 2026. The five conditions the criteria refer to are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

From around March 2027, people with a BMI of 40 or above and three of the five conditions are expected to become eligible. Each phase also carries lower BMI thresholds for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK clinical guidance. Meeting the criteria is necessary but not sufficient, NHS patients must take part in supervised diet and activity support, and access still depends on local commissioning.

For anyone who doesn't meet those criteria or doesn't want to wait, a private prescription route through a GPhC-registered pharmacy remains an option. Private eligibility for tirzepatide follows the licensed indications: BMI 30 or above, or 27-plus alongside a relevant condition. The experiences of people already on treatment may help you gauge whether the private route makes sense for your situation, and our page on what weight loss injections cost in the UK covers what a realistic private price includes.

The oral tablet and what it changes for people who don't want injections

The headline that surprised many people: on 11 June 2026, the MHRA approved an oral semaglutide tablet for weight management (the first in Europe) under the Wegovy brand. It isn't a new molecule; it's the same semaglutide, co-formulated to make oral absorption possible. The dosing ladder runs 1.5 mg, 4 mg, 9 mg and 25 mg, each step requiring at least a month before moving up.

The trial evidence comes from the OASIS 4 study, which reported roughly 13.6% average weight loss over 64 weeks versus around 2.4% for placebo, with higher figures among participants who stayed fully adherent. Gastrointestinal effects were common (around 74% of participants on the active tablet reported them, versus 42% on placebo) though most were described as mild to moderate and settled over time.

The tablet is taken first thing in the morning on an empty stomach, with a small amount of plain water, and you wait at least 30 minutes before anything else by mouth, including coffee. No refrigeration needed, which matters for people who travel frequently. This is genuinely a new development in the weight-loss medicine landscape, though whether it's the right fit for any individual still requires a clinical assessment. It isn't available on the NHS yet; a NICE appraisal would be needed first.

The safety story running alongside all of this

Rapid expansion in prescribing brings safety news alongside it. In January 2026, the MHRA issued a formal Drug Safety Update reminding prescribers and patients that acute pancreatitis is a recognised, if infrequent, risk with GLP-1 medicines. The signal to act on: severe stomach pain that radiates toward the back, with or without vomiting, that doesn't ease. That warrants urgent medical attention, not waiting for your next check-in.

The counterfeit problem has not gone away. Around 20 million doses of illegally traded weight-loss medicines (estimated street value roughly £45 million) were seized in 2025, and the first known UK site manufacturing fake tirzepatide pens was raided in Northampton in October of that year. Sellers operating without a legitimate prescription pathway, particularly on social media, are the source. The practical check takes under a minute: look up any online pharmacy on the GPhC register before ordering anything. If it isn't listed, don't use it.

Our clinical team at nume keeps across all of this (new approvals, updated safety guidance, and shifts in NHS eligibility) because all of it affects how we review consultations. If you want a prescriber's eye on your specific circumstances, you can read more about how a weight loss injection works and who it suits before starting a free consultation that puts your case in front of a real clinician, not an automated system, on the same day you apply.